{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Oncotherapeutics", "query": { "sponsor": "Oncotherapeutics" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Oncotherapeutics&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T21:59:38.773Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02285101", "title": "Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "PEG-BCT-100", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bio-Cancer Treatment International Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2014-11", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 2, "location_summary": "San Diego, California • Santa Monica, California", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285101" }, { "nct_id": "NCT06225310", "title": "A Trial of Selinexor, Ruxolitinib and Methylprednisolone", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2024-08-06", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06225310" }, { "nct_id": "NCT02188368", "title": "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "POM", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "CFZ", "type": "DRUG" }, { "name": "BTZ", "type": "DRUG" }, { "name": "CLA", "type": "DRUG" }, { "name": "CY", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-07-07", "completion_date": "2020-10-23", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 12, "location_summary": "Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188368" }, { "nct_id": "NCT01695330", "title": "Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Subcutaneous bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2012-05", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01695330" }, { "nct_id": "NCT00085345", "title": "Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "Refractory Plasma Cell Neoplasm" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" }, { "name": "ascorbic acid", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "chemosensitization/potentiation", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 19, "location_summary": "Glendale, Arizona • Bakersfield, California • Campbell, California + 16 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085345" }, { "nct_id": "NCT01541332", "title": "Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin (PLD)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-02", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 8, "location_summary": "Burbank, California • Encinitas, California • Fresno, California + 5 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01541332" }, { "nct_id": "NCT01697839", "title": "Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma", "Peripheral Neuropathy" ], "interventions": [], "intervention_types": [], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2012-06", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2018-03-05", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 3, "location_summary": "Highland, California • West Hollywood, California • Hinsdale, Illinois", "locations": [ { "city": "Highland", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Hinsdale", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697839" }, { "nct_id": "NCT03104270", "title": "Combination Study for High Risk Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-03-13", "completion_date": "2020-01-23", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 6, "location_summary": "Encinitas, California • Fountain Valley, California • Monterey, California + 3 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104270" }, { "nct_id": "NCT02206425", "title": "Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "PLD", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-09", "completion_date": "2018-03-06", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 12, "location_summary": "Bakersfield, California • Concord, California • Encinitas, California + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206425" }, { "nct_id": "NCT01160484", "title": "Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "DVD-R", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2009-09", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2015-05-04", "last_synced_at": "2026-09-27T21:59:38.773Z", "location_count": 8, "location_summary": "Bakersfield, California • Fresno, California • Loma Linda, California + 5 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160484" } ] }